NAD+ vs SS-31 (Elamipretide)
A side-by-side research comparison of NAD+ and SS-31 (Elamipretide) across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | NAD+ | SS-31 (Elamipretide) |
|---|---|---|
| Full name | Nicotinamide Adenine Dinucleotide (NAD+ / NMN / NR) | SS-31 / Elamipretide (Bendavia) |
| Category | Anti-Aging | Anti-Aging |
| Status | Research compound | Investigational |
| Mechanism | NAD+ serves as cofactor for sirtuins (SIRT1-7), PARPs (DNA repair), and CD38. Declining NAD+ impairs mitochondrial function and epigenetic maintenance. Restoration reactivates longevity pathways. | Targets cardiolipin in inner mitochondrial membrane, stabilizes cytochrome c binding, optimizes electron transfer efficiency, and reduces mitochondrial ROS by 50%. |
| Molecular weight | 663.4 Da | 640.8 Da |
| Half-life | 1-4 hours (IV), 4-8h (oral precursors) | 4-6 hours |
| Bioavailability | 100% (IV), variable (oral 5-30%) | High (SubQ) |
| Typical dose | 250-500mg IV or 500-1000mg NMN oral | 5-40 mg |
| Frequency | Weekly (IV) or Daily (oral) | Daily |
| Route | IV infusion or Oral (precursors) | Subcutaneous or IV |
NAD+ reported benefits
- Restored cellular energy
- Enhanced DNA repair
- Sirtuin activation
- Improved mitochondrial function
- Cognitive clarity
- Anti-aging
SS-31 (Elamipretide) reported benefits
- Mitochondrial function optimization
- Reduced oxidative stress
- Cardioprotection
- Improved exercise capacity
- Renal protection
- Cellular energy
Related comparisons
Research and educational reference only. Not medical advice.